Belzutifan
技术包 · 片剂 · 40 mg
技术包ASMF（在编）Confidentiality：高保密
- INN / Generic Name
- Belzutifan
- Dosage Form
- 片剂
- Strength
- 40 mg
- Therapy Area
- Anti-cancer
- Indication
- VHL 相关肾细胞癌 / 胰腺神经内分泌肿瘤
- Current Status
- 技术包待转移 + 待本地注册（专利期内）
- GMP Certification
- GMP-like（自有基地）
- CEP
- No
- DMF Type
- ASMF（在编）
- Stability Data
- 18 months
- BE Required
- Yes
- Registration Pathway
- NP + 技术转移（FSO+）
- MOQ
- 1 个项目
- Lead Time
- 150 天
- Price Range
- 技术包授权 US$ 400k-900k
Registrable Markets
BrazilMoroccoAlgeria
Process / Sequence / Exact Price
🔒 Sign a CDA to view process / price / customer
Per our compliance red line, before a CDA is signed we do not disclose sequences, full structures, detailed processes, real customer names or exact prices of pre-launch pipelines. Once you raise an RFQ, the system auto-generates a CDA template; upon admin approval the full data room unlocks.